Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 8/20 | 0.39 |
| ▸ | RAB9A | P51151 | 8/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.39 |
| ▸ | MAPT | P10636 | 6/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | CASP3 | P42574 | 2/20 | 0.37 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.37 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 2/20 | 0.37 |
| ▸ | KLK7 | P49862 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | TEK | Q02763 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16250612 | 0.83 | MLLT1 (0.49) | KITNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL16241752 | 0.83 | KIT (0.60) | KITNPC1RAB9AMAPTKMT2A | |
| SCHEMBL13813508 | 0.77 | KIT (0.77) | KITABL1KDR | |
| SCHEMBL17936025 | 0.76 | RAB9A (0.60) | KITNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL24696591 | 0.75 | KIT (0.72) | KITABL1KDRTEK | |
| SCHEMBL16250589 | 0.75 | KIT (0.67) | KITNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL17936108 | 0.74 | KIT (0.50) | KITNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL22300442 | 0.74 | KIT (0.55) | KITNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL15907178 | 0.74 | BCAT2 (0.54) | KITNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL22299751 | 0.73 | KMT2A (0.56) | KITNPC1RAB9AMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493473-B2 | Processes for making ponatinib and intermediates thereof | APICORE US LLC (US) | 2016-11-15 | — | — | US | disclosed |
| US-20160108053-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | APICORE US LLC (US) | 2016-04-21 | — | — | US | disclosed |
| US-20140343282-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | APICORE, LLC (US) | 2014-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108053-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | ABL1, KRAS, ROS1 | KIT 533/4885NPC1 3261/4885RAB9A 1149/4885 |
| US-20140343282-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | ABL1, KRAS, ROS1 | KIT 533/4885NPC1 3261/4885RAB9A 1149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.